

Adi Diab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2467818/publications.pdf>

Version: 2024-02-01

94
papers

11,283
citations

87888

38
h-index

64796

79
g-index

100
all docs

100
docs citations

100
times ranked

15439
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103. | 12.6 | 3,126 |
| 2 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837. | 9.4 | 785 |
| 3 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, . | 12.4 | 689 |
| 4 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654. | 30.7 | 592 |
| 5 | Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640. | 12.6 | 369 |
| 6 | Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838. | 3.4 | 270 |
| 7 | Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396. | 7.0 | 261 |
| 8 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193. | 10.7 | 233 |
| 9 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441. | 30.7 | 216 |
| 10 | Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106. | | 203 |
| 11 | Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3. | 16.8 | 203 |
| 12 | Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176. | 1.3 | 186 |
| 13 | A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721. | 9.4 | 180 |
| 14 | Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1695-1705. | 1.9 | 177 |
| 15 | Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37. | | 174 |
| 16 | Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319. | | 164 |
| 17 | Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251. | 4.5 | 160 |
| 18 | Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173. | 9.4 | 158 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607. | 1.6 | 156 |
| 20 | Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2061-2064. | 0.9 | 141 |
| 21 | Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515. | 0.7 | 138 |
| 22 | Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103. | | 130 |
| 23 | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661. | 12.8 | 124 |
| 24 | Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, . | 3.8 | 120 |
| 25 | Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14. | | 118 |
| 26 | Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6. | 16.8 | 115 |
| 27 | Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537. | | 105 |
| 28 | A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205. | 5.2 | 95 |
| 29 | Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428. | 7.0 | 89 |
| 30 | Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. , 2019, 7, 237. | | 88 |
| 31 | Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909. | 3.4 | 86 |
| 32 | IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865. | 3.4 | 76 |
| 33 | Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. <i>Nature Communications</i> , 2020, 11, 660. | 12.8 | 68 |
| 34 | Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. <i>Nature Communications</i> , 2017, 8, 1447. | 12.8 | 67 |
| 35 | Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 81. | 17.0 | 62 |
| 36 | Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e207911. | 5.9 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 553-561. | 4.2 | 57 |
| 38 | Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolmunology</i> , 2016, 5, e1136044. | 4.6 | 55 |
| 39 | Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925. | 1.6 | 55 |
| 40 | A case report of Grover's disease from immunotherapy—a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55. | | 50 |
| 41 | Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086. | 1.3 | 48 |
| 42 | Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018, 24, 5735-5743. | 7.0 | 48 |
| 43 | Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105. | 3.4 | 46 |
| 44 | Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283. | 4.5 | 45 |
| 45 | High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67. | 0.6 | 45 |
| 46 | NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3006-3006. | 1.6 | 44 |
| 47 | Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895. | 7.0 | 42 |
| 48 | Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056. | 7.1 | 41 |
| 49 | The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients' Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 7-18. | 1.4 | 40 |
| 50 | Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773. | 1.3 | 38 |
| 51 | A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 71-83. | 7.0 | 37 |
| 52 | Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970. | 12.8 | 34 |
| 53 | Tilsofolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013. | 9.4 | 32 |
| 54 | Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis. <i>Oncolmunology</i> , 2021, 10, 1877415. | 4.6 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <i>Endocrine-Related Cancer</i> , 2021, 28, 419-431. | 3.1 | 29 |
| 56 | Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510. | 2.8 | 28 |
| 57 | Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636. | 1.3 | 27 |
| 58 | Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. <i>Onc Immunology</i> , 2021, 10, 1927313. | 4.6 | 27 |
| 59 | Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1939-1949. | 4.2 | 27 |
| 60 | Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2021, 113, 532-542. | 6.3 | 25 |
| 61 | Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031. | 3.7 | 23 |
| 62 | Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441. | 1.6 | 23 |
| 63 | Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288. | 7.0 | 21 |
| 64 | Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. <i>Frontiers in Immunology</i> , 2020, 11, 590494. | 4.8 | 21 |
| 65 | Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175. | 2.4 | 20 |
| 66 | Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760. | 3.7 | 20 |
| 67 | Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790. | 1.3 | 18 |
| 68 | Cytokines in the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 83. | 4.0 | 17 |
| 69 | Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449. | | 16 |
| 70 | The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299. | 2.8 | 15 |
| 71 | Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818. | | 14 |
| 72 | LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983. | 4.1 | 12 |
| 74 | Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052. | 1.0 | 11 |
| 75 | Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202. | 4.1 | 9 |
| 76 | Melanoma of the External Auditory Canal: A Review of Seven Cases at a Tertiary Care Referral Center. <i>Laryngoscope</i> , 2021, 131, 165-172. | 2.0 | 9 |
| 77 | Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9510-9510. | 1.6 | 8 |
| 78 | Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419. | | 8 |
| 79 | PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913. | 2.4 | 7 |
| 80 | TERT amplification but not activation of canonical Wnt/ β -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074. | 5.5 | 6 |
| 81 | Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3133-TPS3133. | 1.6 | 6 |
| 82 | Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. <i>European Urology</i> , 2022, 82, 365-373. | 1.9 | 6 |
| 83 | Tocilizumab in combination with ipilimumab and nivolumab in solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9600-TPS9600. | 1.6 | 5 |
| 84 | Metastatic Melanoma of the Optic Nerve Sheath. <i>Neuro-Ophthalmology</i> , 2018, 42, 187-190. | 1.0 | 4 |
| 85 | Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9549-9549. | 1.6 | 4 |
| 86 | CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9601-TPS9601. | 1.6 | 3 |
| 87 | Checkpoint inhibitor induced glomerulonephritis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15083-e15083. | 1.6 | 2 |
| 88 | FRI0604...Successful treatment of arthritis induced by checkpoint inhibitors with anti-interleukin-6 receptor antibody: a case series. , 2017, , . | | 1 |
| 89 | Radiologic features of immune checkpoint inhibitor-related nephritis with clinical correlation in biopsy-proven cases.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14585-e14585. | 1.6 | 1 |
| 90 | THU0656...IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND RHEUMATOLOGIC DISEASES: A SYSTEMATIC REVIEW OF THE LITERATURE. , 2019, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 92 | A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).. Journal of Clinical Oncology, 2018, 36, TPS9598-TPS9598. | 1.6 | 0 |
| 93 | Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood, 2020, 136, 1-1. | 1.4 | 0 |
| 94 | Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.. Journal of Clinical Oncology, 2022, 40, TPS12147-TPS12147. | 1.6 | 0 |